Related Experiment Video
Updated: Sep 19, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer
Irfan Cicin1, Berivan Karatekin2, Esra Güzelaltuncekic3
1Medical Faculty, Department of Medical Oncology Oncology, Istinye University, Istanbul, Turkey.
Introduction:
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies and immune checkpoint inhibitors, many patients with advanced NSCLC experience disease progression, necessitating novel therapeutic approaches like antibody-drug conjugate (ADC).
Areas Covered:
Sacituzumab govitecan, a trophoblast cell surface antigen 2 (Trop-2) - directed ADC, has emerged as a potential treatment for advanced NSCLC This review evaluates its mechanism of action, clinical efficacy, safety profile, and potential in combination therapies, particularly in heavily pretreated patients. A literature search was conducted using PubMed with keywords 'sacituzumab govitecan' and 'lung cancer,' incorporating relevant studies, including the EVOKE-01 trial.
Expert Opinion:
Sacituzumab govitecan offers a promising alternative for patients unresponsive to conventional treatments. While it demonstrates encouraging response rates and manageable toxicity, further research is needed to refine patient selection and optimize combination strategies. Ongoing trials, such as KEYNOTE-D46/EVOKE-3 May 2001define its role in first-line NSCLC treatment.
Insights
Sacituzumab govitecan, a novel antibody-drug conjugate (ADC), shows promise for advanced non-small cell lung cancer (NSCLC) patients. This Trop-2 targeted therapy offers a new option for those unresponsive to existing treatments.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Despite advances, many advanced NSCLC patients face disease progression, necessitating novel therapies.
- Antibody-drug conjugates (ADCs) represent a promising therapeutic avenue for NSCLC.
Purpose of the Study:
- To review the mechanism of action, clinical efficacy, and safety of sacituzumab govitecan for advanced NSCLC.
- To evaluate the potential of sacituzumab govitecan in combination therapies.
- To assess its role in heavily pretreated NSCLC patients.
Main Methods:
- Literature search using PubMed with keywords 'sacituzumab govitecan' and 'lung cancer'.
- Inclusion of relevant studies, including the EVOKE-01 trial.
- Evaluation of mechanism of action, clinical efficacy, safety, and combination strategies.
Main Results:
- Sacituzumab govitecan demonstrates encouraging response rates in advanced NSCLC.
- The ADC exhibits a manageable safety profile.
- It offers a potential alternative for patients resistant to conventional therapies.
Conclusions:
- Sacituzumab govitecan is a promising treatment option for advanced NSCLC, particularly in heavily pretreated populations.
- Further research is needed to optimize patient selection and combination strategies.
- Ongoing trials will define its role in first-line NSCLC treatment.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017